Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

被引：0
|
作者：
Llovet, Josep M.
Singal, Amit G.
Villanueva, Augusto
Finn, Richard S.
Kudo, Masatoshi
Galle, Peter R.
Wang, Chunxiao
Widau, Ryan C.
Gugel, Elena Gonzalez
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, New York, NY 10029 USA
[2] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[3] Icahn Sch Med Mt Sina, Dept Med, Div Liver Dis, Mt Sinai, NY USA
[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[6] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly, Indianapolis, IN USA
[9] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4146
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
    Llovet, Josep M.
    Singal, Amit G.
    Villanueva, Augusto
    Finn, Richard S.
    Kudo, Masatoshi
    Galle, Peter R.
    Ikeda, Masafumi
    Callies, Sophie
    McGrath, Louise M.
    Wang, Chunxiao
    Abada, Paolo
    Widau, Ryan C.
    Gonzalez-Gugel, Elena
    Zhu, Andrew X.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2297 - 2305
  • [2] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Llovet, J. M.
    Finn, R. S.
    Kang, Y-K.
    Yen, C. J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Ohno, I.
    Daniele, B.
    Vogel, A.
    Yamashita, T.
    Hsu, C-H.
    Meyer, T.
    Widau, R.
    Schelman, W.
    Wang, C.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein
    Yen, Chih-Chieh
    Yen, Chia-Jui
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (02) : 157 - 166
  • [4] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Andrew X. Zhu
    Richard S. Finn
    Yoon-Koo Kang
    Chia-Jui Yen
    Peter R. Galle
    Josep M. Llovet
    Eric Assenat
    Giovanni Brandi
    Kenta Motomura
    Izumi Ohno
    Bruno Daniele
    Arndt Vogel
    Tatsuya Yamashita
    Chih-Hung Hsu
    Guido Gerken
    John Bilbruck
    Yanzhi Hsu
    Kun Liang
    Ryan C. Widau
    Chunxiao Wang
    Paolo Abada
    Masatoshi Kudo
    British Journal of Cancer, 2021, 124 : 1388 - 1397
  • [5] Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
    Kang, Y-K.
    Kudo, M.
    Lim, H-Y.
    Hsu, C-H.
    Vogel, A.
    Brandi, G.
    Cheng, R.
    Carton, I.
    Abada, P.
    Hsu, Y.
    Zhu, A.
    Yen, C-J.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [6] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Zhu, Andrew X.
    Finn, Richard S.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Vogel, Arndt
    Yamashita, Tatsuya
    Hsu, Chih-Hung
    Gerken, Guido
    Bilbruck, John
    Hsu, Yanzhi
    Liang, Kun
    Widau, Ryan C.
    Wang, Chunxiao
    Abada, Paolo
    Kudo, Masatoshi
    BRITISH JOURNAL OF CANCER, 2021, 124 (08) : 1388 - 1397
  • [7] Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
    Kudo, M.
    Galle, P. R.
    Motomura, K.
    Assenat, E.
    Merle, P.
    Brandi, G.
    Daniele, B.
    Okusaka, T.
    Tomasek, J.
    Borg, C.
    Zagonel, V.
    Morimoto, M.
    Pracht, M.
    Finn, R. S.
    Llovet, J.
    Homma, G.
    Jen, M-H.
    Shinozaki, K.
    Yoshikawa, R.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 292 - 292
  • [8] Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
    Llovet, J.
    Kudo, M.
    Kang, Y-K.
    Yen, C-J.
    Finn, R. S.
    Galle, P. R.
    Assenat, E.
    Motomura, K.
    Okusaka, T.
    Berg, T.
    Hsu, C-H.
    Ikeda, M.
    Hsu, Y.
    Liang, K.
    Widau, R.
    Schelman, W.
    O'Brien, L.
    Gao, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 293 - +
  • [9] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study
    Zhu, Andrew X.
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie Tung-Ping
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari David
    Pfiffer, Tulio Eduardo Flesch
    Okusaka, Takuji
    Kubackova, Katerina
    Trojan, Jorg
    Sastre, Javier
    Chau, Ian
    Chang, Shao-Chun
    Abada, Paolo
    Yang, Ling
    Hsu, Yanzhi
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
    Finn, Richard S.
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep
    Assenat, Eric
    Brandi, Giovanni
    Lim, Ho Yeong
    Pracht, Marc
    Rau, Kun Ming
    Merle, Philippe
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Shin, Dongbok
    Gerken, Guido
    Abada, Paolo
    Hsu, Yanzhi
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345